ORGO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
45.5M
+3.9%
43.8M
+17.5%
37.2M
-83.5%
225.6M
+49.5%
150.9M
Cost of Revenue
0
0
0
0
0
Gross Profit
45.5M
+3.9%
43.8M
+17.5%
37.2M
-83.5%
225.6M
+49.5%
150.9M
Operating Expenses
74.9M
-20.9%
94.7M
-10.7%
106.1M
-34.6%
162.3M
+24.7%
130.1M
R&D
8.0M
-56.5%
18.3M
+20.7%
15.2M
+47.4%
10.3M
-22.2%
13.2M
SG&A
45.1M
-16.5%
54.0M
-17.2%
65.2M
-34.9%
100.2M
+25.6%
79.7M
Operating Income
-29489000
+42.2%
-50992000
+26.0%
-68891000
-208.9%
63.3M
+205.3%
20.7M
EBITDA
-25129000
+46.4%
-46891000
+20.5%
-59009000
-184.2%
70.1M
+173.8%
25.6M
Net Income
-29629000
+69.2%
-96267000
-81.1%
-53156000
-221.6%
43.7M
+102.6%
21.6M
EPS (Basic)
$-0.25
+67.5%
$-0.77
-75.0%
$-0.44
-257.1%
$0.28
+154.5%
$0.11
EPS (Diluted)
$-0.25
+67.5%
$-0.77
-75.0%
$-0.44
-269.2%
$0.26
+136.4%
$0.11
Shares (Diluted)
129.0M
+0.2%
128.7M
+0.7%
127.8M
-6.7%
137.0M
+4.7%
130.8M
Organogenesis (ORGO) — Financials